분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-14 17:58:34 , Hit : 1067
 Gilead hepatitis C drug highly effective in cirrhosis patients


Reuters
By Ransdell Pierson
November 11, 2014 11:29 AM


      
By Ransdell Pierson

(Reuters) - Gilead Sciences Inc on Tuesday said its new Harvoni drug for hepatitis C achieved cure rates of 96 percent to 97 percent in a study of patients who had cirrhosis and had failed to benefit from prior treatments.

The data bolsters the attractiveness of Harvoni, a combination drug that U.S. regulators approved last month and whose $95,000 cost for a course of treatment has raised complaints from insurers and politicians.

The Gilead study involved 155 patients with cirrhosis and the most common genotype 1 form of the liver virus. They previously had failed to benefit from standard older treatments that included protease inhibitors as well as interferon and ribavirin, drugs that can cause harsh side effects and must be taken for almost a year.

All patients received Harvoni, a once-daily pill containing Gilead's Sovaldi and ledipasvir. The combination eliminates the need to take interferon and ribavirin with Sovaldi.

In one group taking Harvoni alone for 24 weeks, the cure rate was 97 percent. It was 96 percent for patients who received Harvoni plus ribavirin for 12 weeks.

Three far smaller Gilead studies evaluated Sovaldi, a so-called nucleotide, in combination with the company's experimental NS5A inhibitor GS-5816, with and without ribavirin for eight or 12 weeks.

Of patients taking the combination for 12 weeks without ribavirin, sustained cures were seen in 100 percent of genotype 1 patients, with and without cirrhosis, and in 88 percent of those with the less common genotype 3 form of the virus, with cirrhosis.

Shares of Gilead were up 1.4 percent at $108.54 in morning trading.

(Reporting by Ransdell Pierson; Editing by Lisa Von Ahn)







987   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1923
986   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1128
985   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1492
984   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1159
983   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1595
982   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1659
981   AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1187
  Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1067
979   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1468
978   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1665
977   간 이식 환자들의 C형 간염에 효과적인 병용 요법  이성욱 2014/11/13 1608
976   J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1523
975   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1279
974   실험실에서 만든 인공위장  이성욱 2014/11/04 1222
973   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1493
972   어떻게 복잡한 생명은 진화했는가?  이성욱 2014/10/31 1601
971   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1563
970   As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  이성욱 2014/10/31 1348
969   암의 우군-엑소좀(exosome)  이성욱 2014/10/29 2788
968   이웃의 정상세포를 감염시키는 암세포  이성욱 2014/10/27 1464

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN